CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

durvalumab

Last Updated: December 23, 2020
Result type: Reports
Project Number: PC0234-000
Product Line: Reimbursement Review

Generic Name: durvalumab

Brand Name: Imfinzi

Manufacturer: AstraZeneca Canada Inc.

Therapeutic Area: Extensive-stage small cell lung cancer

Indications: IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Manufacturer Requested Reimbursement Criteria1: As per Health Canada indication: in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Submission Type: Initial

Tumour Type: Lung

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule1: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 03, 2020
Call for patient/clinician input closedDecember 24, 2020
Clarification:

- Patient input submission received from Lung Cancer Canada and Lung Health Foundation

Submission receivedDecember 01, 2020
Submission acceptedDecember 15, 2020
Review initiatedDecember 16, 2020
Draft CADTH review report(s) provided to sponsor for commentMarch 22, 2021
Deadline for sponsors commentsMarch 31, 2021
CADTH responses on draft review report(s) provided to sponsorMay 03, 2021
Expert committee meeting (initial)May 13, 2021
Draft recommendation issued to sponsorMay 26, 2021
To
May 28, 2021
Draft recommendation posted for stakeholder feedback-